A 55-year-old man presented to the emergency department (ED) with diffuse abdominal pain, vomiting, and anuria following a night of heavy alcohol intake. The patient’s medical history included ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving ...

TINU syndrome affects kidneys and eyes, with symptoms like fatigue, polyuria, and bilateral anterior uveitis, primarily in adolescents and young adults. Diagnosis is challenging due to the temporally ...

Hydroxychloroquine exposure in patients with lupus nephritis was associated with a substantially lower risk for estimated glomerular filtration rate (eGFR) decline of ≥ 30%, particularly among those ...

AKI can be classified as prerenal, intrinsic, or postrenal, with KDIGO criteria guiding diagnosis. New biomarkers like NGAL and cystatin C allow earlier and more precise detection of AKI. Preventing ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

1 Department of Nephrology, Westchester Medical Center Advanced Physician Services, Mid-Hudson Regional Hospital, Poughkeepsie, NY, United States 2 Department of Pathology, Montefiore Medical Center, ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

An expert briefly describes the study “Evaluation of Clinical Efficacy of Systemic Antibiotics for Treatment of Acute Pyelonephritis in Adults: A Network Meta-Analysis of Randomized Controlled Trials, ...

While Roche’s Gazyva has been on the market for a dozen years and has won four approvals from the FDA, it is making a late push to gain a nod in what would be its most important indication—lupus ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...